



## **Workshop on Challenges, Insights, and Future Directions for Mouse and Humanized Models in Cancer Immunology and Immunotherapy**

### **Thursday, November 10, 2016**

8:00 – 8:05 a.m.                      **Welcome & Introductions**  
Andrew Zloza, MD, PhD – *Rutgers Cancer Institute of New Jersey*

#### **Session I: Introduction to Models of Immunotherapy**

*2.0 AMA PRA Category 1 Credits™*

8:05 – 8:35 a.m.                      **Major Questions Related to Immunotherapies that Require Models to Address**  
Mario Sznol, MD – *Yale School of Medicine*

8:35 – 9:05 a.m.                      **Overview of Mouse-Mouse Models**  
Marcus W. Bosenberg, MD, PhD – *Yale School of Medicine*

9:05 – 9:35 a.m.                      **Overview of Humanized Mice Models**  
A. Karolina Palucka, MD, PhD – *The Jackson Laboratory for Genomic Medicine*

9:35 – 10:05 a.m.                      **Overview of Patient-derived Xenograft (PDX) Models**  
Andrew Zloza, MD, PhD – *Rutgers Cancer Institute of New Jersey*

10:05 – 10:35 a.m.                      *Break*

#### **Session II: Modeling the Tumor Microenvironment**

*2.0 AMA PRA Category 1 Credits™*

10:35 – 11:05 a.m.                      **Evaluation of the Tumor Microenvironment**  
Mark B. Headley, PhD – *University of California San Francisco*

11:05 – 11:35 a.m.                      **Factors Affecting Tumor – Microenvironment Interactions**  
Lisa M. Coussens, PhD – *Oregon Health and Sciences University*

11:35 – 12:05 p.m.                      **Vascular Regulation of the Tumor Microenvironment and Immune Responses**  
Amanda Lund, PhD – *Oregon Health & Science University*

12:05 – 12:35 p.m.                      **Components of the Tumor Microenvironment that Module Tumor Immune Responses**  
Kwok-Kin Wong, MD, PhD – *Dana-Farber Cancer Institute, Harvard Medical School*

12:35 – 1:25 p.m.                      *Lunch*



### Session III: Modeling Evaluation of Immune Therapies

1.75 AMA PRA Category 1 Credits™

- 1:25 – 2:00 p.m.                      **Evaluation of Immune Checkpoint Inhibitors in Mice**  
Arlene H. Sharpe, MD, PhD – *Harvard Medical School*
- 2:00 – 2:35 p.m.                      **Reevaluating the Role of IDOI in Brain Cancer; Humanized Immunocompetent Mice Take Center Stage**  
Derek A. Wainwright, PhD – *Northwestern University*
- 2:35 – 3:10 p.m.                      **Developing New Immunotherapies in Preclinical Models and Humans**  
Elizabeth M. Jaffee, MD – *The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University*
- 3:10 – 3:45 p.m.  
*Non-CE Presentation*                      **What Information Provided by Models will Inform Immune Drug Development and Use?**  
Philip Gotwals, PhD – *Novartis Institutes for BioMedical Research, Inc.*
- 3:45 – 4:05 p.m.                      *Break*

### Session IV: Panel Discussion and Future Directions

- 4:05 – 4:45 p.m.  
*Non-CE Session*                      **Future Directions for the Development and Use of Cancer Immune Models**  
*Moderator:*  
Marcus W. Bosenberg, MD, PhD – *Yale School of Medicine*
- Panelists:*  
Lisa M. Coussens, PhD – *Oregon Health and Sciences University*  
Philip Gotwals, PhD – *Novartis Institutes for BioMedical Research, Inc.*  
Elizabeth M. Jaffee, MD – *The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University*  
A. Karolina Palucka, MD, PhD – *The Jackson Laboratory for Genomic Medicine*  
Arlene H. Sharpe, PhD – *Harvard Medical School*  
Mario Sznol, MD – *Yale School of Medicine*  
Kwok-Kin Wong, MD, PhD – *Dana-Farber Cancer Institute, Harvard Medical School*  
Andrew Zloza, MD, PhD – *Rutgers Cancer Institute of New Jersey*
- 4:45 – 5:00 p.m.                      **Closing Remarks**  
Marcus W. Bosenberg, MD, PhD – *Yale School of Medicine*

### Social Activity

- 5:30 – 6:30 p.m.                      *Presidential Reception & State of SITC: Membership Business Meeting*